Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-705-0
CAS number: 98-83-9
Short description of key information on bioaccumulation potential result: The toxicokinetics of alpha-methylstyrene were extensively investigated in rats with oral, intravenous and inhalative exposure:i.v.: 10 mg/kgoral: 1000 mg/kginhalation: 300 or 900 ppm over 6 hrs (nose-only).Alpha-methylstyrene was readily metabolized to form products that were chiefly excreted in the urine. There was little accumulation of radiolabeled equivalents in the tissues, so that a bioaccumulation potential can be excluded.
Male F344/N rats were exposed to
alpha-methylstyrene via intravenous or nose-only inhalation exposure. In
both studies, the substance was eliminated primarily in the urine
(approximately 90 %) within 72 hours, with volatile breath and faeces
accounting for only a small amount (1 - 3 %) of elimination. In the
inhalation study, the elimination half-life was calculated at 3 to 5
hours, with the highest concentrations of alpha-methylstyrene-derived
radioactivity retained in the adipose tissue, urinary bladder, liver,
kidney, and skin. Following intravenous dosing, the kidney, heart, lung,
liver, urinary bladder, and spleen retained the highest concentrations
of radioactivity. In both the intravenous study and the inhalation
study, the major urinary metabolites of alpha-methylstyrene were the
glucuronide conjugate of 2-phenyl-1,2-propanediol and atrolactic acid.
In the inhalation study, the major metabolites in the blood were
2-phenyl-1,2-propanediol and 2-phenylpropionic acid.
The proposed metabolic pathway for
alpha-methylstyrene involves an initial non-stereoselective epoxidation
followed by hydrolysis to form 2-phenyl-1,2-propanediol followed by
either oxidation to atrolactic acid or formation of the glucuronide
conjugate, conjugation with glutathione and subsequent cleavage to the
mercapturate, or rearrangement to form an aldehyde that is oxidized to
yield 2-phenylpropionic acid. The dose-dependent pharmacokinetic
parameters coupled with decreased excretion of 2-phenyl-1,2-propanediol
glucuronide at 900 ppm indicate that glucuronide formation was saturated
at this dose.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again